Table 1 Baseline patient characteristics (n = 103 patients totally)
Patient characteristics | Cutaneous melanoma | Mucosal melanoma | Melanoma of unknown primary | |||
|---|---|---|---|---|---|---|
N | % | N | % | N | % | |
No. patients, % | 83 | 100 | 7 | 100 | 13 | 100 |
Age, years | ||||||
Median (range) | 63 | (29–85) | 63 | (33–37) | 62 | (40–77) |
Sex | ||||||
Male | 53 | 64 | 2 | 29 | 11 | 29 |
Female | 30 | 36 | 5 | 71 | 2 | 71 |
ECOG baseline | ||||||
0 | 51 | 61 | 2 | 29 | 12 | 92 |
1 | 23 | 28 | 5 | 71 | 1 | 8 |
2 | 9 | 11 | – | – | ||
BRAF mutation | ||||||
Not mutated | 29 | 35 | 3 | 43 | 5 | 39 |
Mutated | 17 | 21 | – | 6 | 46 | |
Not known | 37 | 45 | 4 | 57 | 2 | 15 |
Disease stage (all: Stage IV) | ||||||
M1a | 6 | 7 | – | 3 | 23 | |
M1b | 15 | 18 | 2 | 29 | 1 | 8 |
M1c | 62 | 75 | 5 | 71 | 9 | 69 |
LDH | ||||||
<2 ULN | 67 | 81 | 5 | 71 | 11 | 85 |
≥2 ULN | 16 | 19 | 2 | 29 | 2 | 15 |
Brain metastases | ||||||
No | 57 | 69 | 5 | 71 | 10 | 77 |
Yes | 26 | 31 | 2 | 29 | 3 | 23 |
Prior systemic therapy in stage IV (except radiotherapy) | ||||||
No | – | – | – | |||
Yes | 83 | 100 | 7 | 100 | 13 | 100 |
Number of prior systemic therapies | ||||||
1 | 42 | 51 | 6 | 86 | 8 | 62 |
2 | 27 | 33 | – | 3 | 23 | |
≥3 | 13 | 16 | 1 | 14 | 2 | 15 |
Not applicable | 1 | 1 | – | – | ||
Immunotherapy | ||||||
No | 67 | 81 | 7 | 100 | 11 | 85 |
Yes | 16 | 19 | – | 2 | 15 | |
If yes, type of previous immunotherapy | ||||||
Interferon alpha | 11 | 13 | – | 2 | 15 | |
Vaccination | 5 | 6 | – | – | ||
Kinase inhibitors | ||||||
No | 71 | 86 | 7 | 100 | 9 | 69 |
Yes | 12 | 14 | – | 4 | 31 | |
If yes, type of previous kinase inhibitor | ||||||
BRAF inhibitor | 7 | 8 | – | 2 | 15.5 | |
MEK inhibitor | 4 | 5 | 2 | 15.5 | ||
Chemotherapy | ||||||
0 | 9 | 11 | – | 2 | 15 | |
1 | 47 | 57 | 6 | 86 | 8 | 62 |
2 | 20 | 24 | – | 2 | 15 | |
≥3 | 7 | 8 | 1 | 14 | 1 | 8 |